GlassScriptPhysician profile
Srinivas Kodali
NPI 1295979813
$8,736.33
in general payments reported to CMS, 2019-2025
64 companies · $4,426 in 2025
The $4,426 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $16.93 · 2021: $23.34 · 2022: $151 · 2023: $1,112 · 2024: $2,642 · 2025: $4,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,918 · Education: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,918.40 |
| Education | $261.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $574.23 | 2023-2025 | Keytruda, Welireg, Reblozyl |
| Janssen Biotech, INC. | $559.13 | 2024-2025 | Erleada, Tecvayli, Talvey |
| Novartis Pharmaceuticals Corporation | $524.77 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $461.09 | 2024-2025 | Imfinzi, Tagrisso, Enhertu |
| Pfizer INC. | $456.42 | 2023-2025 | |
| Glaxosmithkline, LLC. | $366.55 | 2023-2025 | Ojjaara, Blenrep |
| Genzyme Corporation | $323.41 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.19 | 2019-2025 | Gilotrif |
| Daiichi Sankyo INC. | $301.09 | 2024-2025 | Enhertu, Vanflyta, Datroway |
| E.R. Squibb & Sons, L.L.C. | $249.82 | 2020-2025 | Opdivo, Opdualag |
| Celgene Corporation | $249.10 | 2024-2025 | Reblozyl, Opdivo, Opdualag |
| Jazz Pharmaceuticals INC. | $213.53 | 2024-2025 | |
| Sobi, INC | $191.60 | 2023-2025 | |
| Abbvie INC. | $185.55 | 2024-2025 | |
| Incyte Corporation | $185.11 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $180.86 | 2023-2025 | |
| Puma Biotechnology, INC. | $173.86 | 2023-2025 | Nerlynx |
| Beigene USA, INC. | $171.42 | 2023-2024 | Brukinsa |
| Gilead Sciences, INC. | $168.80 | 2019-2025 | Trodelvy |
| Lilly USA, LLC | $167.55 | 2019-2025 | Verzenio, Jaypirca |
| Bayer Healthcare Pharmaceuticals INC. | $158.86 | 2025 | |
| Astellas Pharma US INC | $129.28 | 2023-2025 | Xtandi, Vyloy, Padcev |
| Deciphera Pharmaceuticals INC. | $129.23 | 2024-2025 | Qinlock, Tgct, Romvimza |
| Eisai INC. | $117.51 | 2019-2025 | |
| Tempus Ai, INC | $111.68 | 2024-2025 | Xt Cdx |
| Karyopharm Therapeutics INC. | $111.64 | 2023-2025 | Xpovio |
| Janssen Pharmaceuticals, INC | $111.57 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Seagen INC. | $110.90 | 2023 | Padcev |
| Apellis Pharmaceuticals, INC. | $109.81 | 2024 | Empaveli |
| Regeneron Healthcare Solutions, INC. | $102.63 | 2024-2025 | Libtayo, Lynozyfic |
| Amgen INC. | $99.99 | 2022 | |
| Sun Pharmaceutical Industries INC. | $95.24 | 2023-2024 | Yonsa, Odomzo |
| Adc Therapeutics America, INC. | $90.94 | 2023-2025 | |
| Boston Scientific Corporation | $83.54 | 2024 | |
| Rigel Pharmaceuticals, INC. | $76.50 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Exelixis INC. | $76.47 | 2019-2025 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $74.51 | 2025 | |
| Tersera Therapeutics LLC | $70.80 | 2025 | Zoladex |
| Ipsen Biopharmaceuticals, INC | $64.74 | 2024-2025 | Onivyde |
| Takeda Pharmaceuticals U.S.A., INC. | $57.57 | 2019-2025 | Ninlaro |
| Mirati Therapeutics, INC. | $53.89 | 2024 | Krazati |
| Genmab U.S., INC. | $52.44 | 2024-2025 | Epkinly |
| Adaptive Biotechnologies Corporation | $49.25 | 2024-2025 | Clonoseq |
| Recordati_rare_diseases_inc. | $48.59 | 2025 | Enjaymo |
| Stemline Therapeutics INC. | $43.67 | 2025 | Orserdu |
| Genentech USA, INC. | $39.83 | 2023-2025 | Venclexta, Gavreto, Tecentriq |
| Array Biopharma INC | $39.79 | 2025 | Tukysa, Braftovi, Mektovi |
| Emd Serono, INC. | $39.38 | 2023-2025 | Bavencio |
| Pharmacosmos Therapeutics INC. | $36.97 | 2025 | Monoferric |
| Blueprint Medicines Corporation | $29.22 | 2024 | Ayvakit |
| Geron Corporation | $27.86 | 2025 | Rytelo |
| Springworks Therapeutics, INC. | $27.81 | 2025 | Ogsiveo |
| Corcept Therapeutics | $27.73 | 2025 | Korlym |
| Ferring Pharmaceuticals INC. | $27.39 | 2025 | Adstiladrin |
| Sumitomo Pharma America, INC. | $25.13 | 2025 | Orgovyx |
| Dendreon Pharmaceuticals LLC | $23.92 | 2025 | Provenge |
| Agios Pharmaceuticals, INC. | $23.42 | 2025 | Pyrukynd |
| Beone Medicines USA, INC. | $21.11 | 2025 | Brukinsa |
| Pharmaessentia USA Corporation | $20.69 | 2023 | Besremi |
| Alnylam Pharmaceuticals INC. | $20.47 | 2025 | Givlaari |
| Nuvation Bio INC. | $18.04 | 2025 | Ibtrozi |
| Azurity Pharmaceuticals, INC. | $16.30 | 2025 | Danziten |
| Tolmar, INC. | $13.47 | 2025 | Eligard, Rubraca |
| Pharmaand Gmbh | $13.47 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srinivas Kodali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.